$35.46
2.16% yesterday
NYSE, Jan 06, 10:19 pm CET

Hims & Hers Health Inc. Stock price

$35.46
-3.66 9.36% 1M
-12.96 26.77% 6M
+2.99 9.21% YTD
+8.56 31.82% 1Y
+29.33 478.47% 3Y
+19.74 125.57% 5Y
+25.66 261.84% 10Y
+25.66 261.84% 20Y
NYSE, Closing price Tue, Jan 06 2026
+0.75 2.16%

New AI Insights on Hims & Hers Health Inc. Insights AI Insights on Hims & Hers Health Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$7.9b
Enterprise Value
$8.2b
Net debt
$341.3m
Cash
$629.7m
Shares outstanding
227.5m
Valuation (TTM | estimate)
P/E
64.3 | 73.5
P/S
3.6 | 3.3
EV/Sales
3.7 | 3.4
EV/FCF
69.0
P/B
13.6
Financial Health
Equity Ratio
67.4%
Return on Equity
26.4%
ROCE
7.4%
ROIC
11.2%
Debt/Equity
1.7
Financials (TTM | estimate)
Revenue
$2.2b | $2.4b
EBITDA
$174.3m | $319.7m
EBIT
$131.8m | $116.4m
Net Income
$133.8m | $107.4m
Free Cash Flow
$119.5m
Growth (TTM | estimate)
Revenue
78.0% | 62.3%
EBITDA
195.2% | 275.7%
EBIT
190.6% | 71.2%
Net Income
32.1% | -14.8%
Free Cash Flow
-20.1%
Margin (TTM | estimate)
Gross
75.0%
EBITDA
7.9% | 13.3%
EBIT
6.0%
Net
6.1% | 4.5%
Free Cash Flow
5.4%
More
EPS
$0.5
FCF per Share
$0.5
Short interest
35.2%
Employees
2k
Rev per Employee
$900.0k
Show more

Is Hims & Hers Health Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Hims & Hers Health Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Hims & Hers Health Inc. forecast:

8x Buy
38%
11x Hold
52%
2x Sell
10%

Analyst Opinions

21 Analysts have issued a Hims & Hers Health Inc. forecast:

Buy
38%
Hold
52%
Sell
10%

Financial data from Hims & Hers Health Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,211 2,211
78% 78%
100%
- Direct Costs 552 552
136% 136%
25%
1,658 1,658
65% 65%
75%
- Selling and Administrative Expenses 1,527 1,527
59% 59%
69%
- Research and Development Expense - -
-
-
174 174
195% 195%
8%
- Depreciation and Amortization 42 42
210% 210%
2%
EBIT (Operating Income) EBIT 132 132
191% 191%
6%
Net Profit 134 134
32% 32%
6%

In millions USD.

Don't miss a Thing! We will send you all news about Hims & Hers Health Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hims & Hers Health Inc. Stock News

Positive
Seeking Alpha
about 13 hours ago
Hims & Hers Health shares are down 30%, but I maintain a Buy rating due to compelling long-term growth levers. HIMS's core business growth is slowing, yet margin expansion, product innovation, and international expansion underpin mid-term shareholder value. GLP-1's legal clarity and new hormone care verticals—testosterone and menopause—offer strong upsell potential and improved retention.
Positive
Seeking Alpha
one day ago
Hims & Hers remains a "Buy" as recent catalysts, including renewed GLP-1 partnership talks and share buybacks, support a rebound thesis. HIMS boasts a sticky, high-margin customer base, expanding into new specialties and diagnostics, with international growth representing a $1 billion medium-term opportunity. Q3 revenue grew 49% y/y to $599 million, beating expectations, with subscriber growth ...
Negative
Forbes
4 days ago
Hims & Hers Health (HIMS) stock has experienced a 7-day losing streak, resulting in total losses of 8.7% over this time frame. The company's market capitalization has plummeted by approximately $699 million in the past week, currently sitting at $7.3 billion.
More Hims & Hers Health Inc. News

Company Profile

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Head office United States
CEO Andrew Dudum
Employees 1,637
Founded 2017
Website www.forhims.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today